Skip to Main content Skip to Navigation
Journal articles

What do we learn from HER2-positive breast cancer genomic profiles?

Abstract : ABSTRACT: Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00491423
Contributor : Yves Le Ster <>
Submitted on : Friday, June 11, 2010 - 3:47:52 PM
Last modification on : Wednesday, August 14, 2019 - 5:36:06 PM
Long-term archiving on: : Friday, September 17, 2010 - 1:26:40 PM

Files

bcr2571_Theillet_edited.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Charles Theillet. What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Research, BioMed Central, 2010, 12 (3), pp.107. ⟨10.1186/bcr2571⟩. ⟨inserm-00491423⟩

Share

Metrics

Record views

223

Files downloads

296